Results 21 to 30 of about 12,098 (189)

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition [PDF]

npj Precision Oncology, 2020
AbstractHistologic transformation from non-small cell to small cell lung cancer has been reported as a resistance mechanism to targeted therapy in EGFR-mutant and ALK fusion-positive lung cancers. Whether small cell transformation occurs in other oncogene-driven lung cancers remains unknown.
Jessica J. Lin, Adam Langenbucher, Pranav Gupta, Satoshi Yoda, Isobel J. Fetter, Marguerite Rooney, Andrew Do, Marina Kem, Kylie Prutisto Chang, Audris Y. Oh, Emily Chin, Dejan Juric, Ryan B. Corcoran, Ibiayi Dagogo-Jack, Justin F. Gainor, James R. Stone, Jochen K. Lennerz, Michael S. Lawrence, Aaron N. Hata, Mari Mino-Kenudson, Alice T. Shaw   +20 more
openaire   +2 more sources

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers. [PDF]

NPJ Precis Oncol
Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA.   +9 more
europepmc   +3 more sources

Rare MYH9-ROS1 Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study

Case Reports in Oncology, 2022
The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include CD74, SDC4, and EZR.
Takeshi Tsuda, Naoki Takata, Takahiro Hirai, Yasuaki Masaki, Shin Ishizawa, Hirokazu Taniguchi   +5 more
doaj   +1 more source

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization [PDF]

Archives of Pathology & Laboratory Medicine, 2019
Context.— The ability to determine ROS1 status has become mandatory for patients with lung adenocarcinoma, as many global authorities have approved crizotinib for patients with ROS1-positive lung adenocarcinoma. Objective.— To present analytical ...
Huang, Richard, Smith, Derek, Le, Catherine, Liu, Wen-Wei, Ordinario, Ellen, Manohar, Chitra, Lee, Michael, Rajamani, Jaya, Truong, Huan, Li, Jing, Choi, Cindy, Li, Jingchuan, Pati, Amrita, Bubendorf, Lukas, Buettner, Reinhard, Kerr, Keith, Lopez-Rios, Fernando, Marchetti, Antonio, Marondel, Ivonne, Nicholson, Andrew, Öz, Ayşim Büge, Pauwels, Patrick, Penault-Llorca, Frédérique, Rossi, Giulio, Thunnissen, Erik, Newell, Amy Hanlon, Pate, Greg, Menzl, Ina   +27 more
openaire   +6 more sources

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

Frontiers in Immunology, 2020
The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable.
Liangliang Cai, Liangliang Cai, Liangliang Cai, Jianchun Duan, Li Qian, Li Qian, Zhijie Wang, Shuhang Wang, Sini Li, Chao Wang, Jie Zhao, Xue Zhang, Hua Bai, Jie Wang   +13 more
doaj   +1 more source

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. [PDF]

PLoS ONE, 2015
AIMS:To compare fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and quantitative real-time reverse transcription-PCR (qRT-PCR) assays for detection of ROS1 fusion in a large number of ROS1-positive lung adenocatcinoma (ADC) patients.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin   +6 more
doaj   +1 more source

Immunohistochemical Detection ofROS1Fusion [PDF]

American Journal of Clinical Pathology, 2016
Patients whose tumors harbor ROS1 translocation may benefit from targeted therapy. Detection of ROS1 rearrangement can be done by three methods: immunohistochemistry, fluorescence in situ hybridization, and molecular assays. Immunohistochemistry would be a cost-effective means to screen for ROS1 translocation, which is uncommon.ROS1 immunostain was ...
Yuhua, Su, Theodore, Goncalves, Dora, Dias-Santagata, Mai P, Hoang   +3 more
openaire   +2 more sources

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

JTO Clinical and Research Reports, 2020
ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development.
Sai-Hong Ignatius Ou, MD PhD, Misako Nagasaka, MD   +1 more
doaj   +1 more source

Mouse model for ROS1-rearranged lung cancer. [PDF]

PLoS ONE, 2013
Genetic rearrangement of the ROS1 receptor tyrosine kinase was recently identified as a distinct molecular signature for human non-small cell lung cancer (NSCLC).
Yasuhito Arai, Yasushi Totoki, Hiroyuki Takahashi, Hiromi Nakamura, Natsuko Hama, Takashi Kohno, Koji Tsuta, Akihiko Yoshida, Hisao Asamura, Michihiro Mutoh, Fumie Hosoda, Hitoshi Tsuda, Tatsuhiro Shibata   +12 more
doaj   +1 more source

Molecular Pathways: ROS1 Fusion Proteins in Cancer [PDF]

Clinical Cancer Research, 2013
Abstract Genetic alterations that lead to constitutive activation of kinases are frequently observed in cancer. In many cases, the growth and survival of tumor cells rely upon an activated kinase such that inhibition of its activity is an effective anticancer therapy.
Kurtis D, Davies, Robert C, Doebele
openaire   +2 more sources